[Penile necrosis, a specific complication of prostatic artery embolization].

Nécrose pénienne, une complication spécifique de l’embolisation prostatique.
Benign prostatic hyperplasia Dysfonction érectile Dysuria Dysurie Embolisation de l’artère prostatique Erectile dysfunction Hypertrophie bénigne de prostate Necrosis Nécrose Prostatic artery embolization

Journal

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie
ISSN: 1166-7087
Titre abrégé: Prog Urol
Pays: France
ID NLM: 9307844

Informations de publication

Date de publication:
Aug 2023
Historique:
received: 11 01 2023
revised: 06 04 2023
accepted: 12 04 2023
medline: 23 10 2023
pubmed: 9 5 2023
entrez: 8 5 2023
Statut: ppublish

Résumé

Endoscopic surgery is the standard treatment for benign prostatic hyperplasia (BPH) refractory to pharmacological treatments. In order to reduce invasiveness and preserve sexual function, prostatic artery embolization (PAE) has been developed. However, the technical difficulties of carrying out this procedure and the results, which have yet to be confirmed, mean that it is not currently recommended. The seriousness of the complications generated should lead to a reflection on the benefit-risk balance. The objective is to report a case of penile ischemia after embolization of the prostatic arteries. A severe complication following prostatic artery embolization (PAE) is reported with its clinical and paraclinical evaluation before and after the procedure as well as the therapeutic management. Penile necrosis following prostatic artery embolization was reported in a 75-year-old patient despite an attempt of deobstruction. Lower urinary tract symptoms worsened postoperatively, associated with glans necrosis and refractory erectile dysfunction. The place of PAE in the therapeutic arsenal of BPH needs to be confirmed. This innovative technique exposes the patient to potentially severe risks such as penile ischemia, not encountered in conventional endoscopic surgical treatment. PAE should not be included in the therapeutic armamentarium for BPH outside of clinical trials.

Identifiants

pubmed: 37156687
pii: S1166-7087(23)00089-1
doi: 10.1016/j.purol.2023.04.003
pii:
doi:

Types de publication

Case Reports English Abstract Journal Article

Langues

fre

Sous-ensembles de citation

IM

Pagination

407-411

Informations de copyright

Copyright © 2023 Elsevier Masson SAS. All rights reserved.

Auteurs

Maxime Pattou (M)

Service d'urologie, hôpital Foch, Suresnes, France. Electronic address: maxime.pattou@gmail.com.

Yann Neuzillet (Y)

Service d'urologie, hôpital Foch, Suresnes, France.

Thierry Lebret (T)

Service d'urologie, hôpital Foch, Suresnes, France.

Laurent Yonneau (L)

Service d'urologie, hôpital Foch, Suresnes, France.

François-Xavier Madec (FX)

Service d'urologie, hôpital Foch, Suresnes, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH